Press/Media
- 25 results
Search results
-
Recurrent Respiratory Papillomatosis and Bevacizumab Treatment
2/10/17
1 item of Media coverage
Press/Media
-
New technique facilitates tumor detection and avoids intervention
4/06/18
1 item of Media coverage
Press/Media
-
Does cytoreductive nephrectomy remain an essential component of care for advanced renal cell carcinoma?
25/06/19
1 item of Media coverage
Press/Media
-
-
Chile is the first Latin American country to obtain "intelligent home" technology
11/12/21
1 item of Media coverage
Press/Media
-
Ipsen: Cabometyx in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma
13/02/23
1 item of Media coverage
Press/Media
-
Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023
14/02/23
1 item of Media coverage
Press/Media
-
Cabometyx® in Combination with Nivolumab Shows Durable Survival Benefits At Over Three-years’ Follow-up in First-line Advanced Renal Cell Carcinoma
14/02/23
2 items of Media coverage
Press/Media
-
Cabometyx and Opdivo show durable survival benefits in first-line advanced renal cell carcinoma
14/02/23
1 item of Media coverage
Press/Media
-
Cabometyx® In Combination With Nivolumab Shows Durable Survival Benefits At Over Three-Years' Follow-Up In First-Line Advanced Renal Cell Carcinoma
13/02/23 → 14/02/23
56 items of Media coverage
Press/Media
-
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
13/02/23 → 14/02/23
18 items of Media coverage
Press/Media
-
-
Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit
15/02/23
1 item of Media coverage
Press/Media
-
Basketball Legend Kareem Abdul-Jabbar Joins No Time to Wait Campaign to Raise Awareness of Atrial Fibrillation and its Symptoms
16/02/23
1 item of Media coverage
Press/Media
-
Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma
13/02/23 → 16/02/23
5 items of Media coverage
Press/Media
-
Komo Plant Based Foods Reports Impressive Revenue Growth with a 160% Increase in Q2
16/02/23
1 item of Media coverage
Press/Media
-
Positive results for Ipsen 's Cabometyx in combination with nivolumab
17/02/23
1 item of Media coverage
Press/Media
-
Nivolumab/cabozantinib shows improvements in long-term survival for RCC
19/02/23
2 items of Media coverage
Press/Media
-
Nivolumab Plus Cabozantinib Benefits Consistent at 3 Years for Renal Cell Carcinoma
21/02/23
1 item of Media coverage
Press/Media
-
Nivolumab-plus cabozantinib improves outcomes in advanced renal cell carcinoma
23/02/23
2 items of Media coverage
Press/Media
-
Nivolumab Plus Cabozantinib Demonstrates Positive Results for Renal Cell Carcinoma
27/02/23
1 item of Media coverage
Press/Media
-
Nivolumab/Cabozantinib Shows Continued Benefit In Frontline Treatment of RCC
28/02/23
1 item of Media coverage
Press/Media
-
Nivolumab plus cabozantinib superior to sunitinib in renal cell carcinoma
3/03/23
2 items of Media coverage
Press/Media